Oncologist hires may 'finish the battle for radiation' in Corner Brook, says advocate
On Friday the Newfoundland and Labrador government announced two radiation oncologists have been recruited to work at the Western Memorial Regional Hospital in Corner Brook.
Gerald Parsons, who has been fighting for better cancer care on the west coast for decades as co-chair of the Western Regional Hospital Action Committee, said he'll be pleased as soon as the first oncologist starts work.
"Hopefully this will finish the battle for radiation," he told CBC Radio's Newfoundland Morning.
Years ago he had no choice but to take his wife to St. John's for cancer treatment and said radiation services in Corner Brook would have made a world of difference.
WATCH | Radiation in Corner Brook means west coast families can stay close to home:
"They say one of the biggest healing processes with cancer is having family around you," he said. "We spent five weeks in St. John's at a hotel."
For Parsons, radiation services on the west coast has been a long time coming.
"It's been a year since [the Western Memorial Regional Hospital] opened up and the service is still not there. All the equipment is here," said Parsons.
In Friday's statement, the Newfoundland and Labrador Health Services said the two oncologists will start work in the summer and fall, and radiation oncology services will be rolled out in three phases.
The ongoing first phase provides CT simulations to eligible patients for radiation planning purposes. Phase two is hoped to begin in late August and include consultations and follow-up appointments in Corner Brook.
The third and final phase of the radiation service roll-out "includes radiation services beginning and continuing to scale up as recruitment and onboarding of specialized staff progresses," said the statement.
Parsons said the announcement is a step closer to his ultimate goal of better health-care services in western Newfoundland.
Download our free CBC News app to sign up for push alerts for CBC Newfoundland and Labrador. Sign up for our daily headlines newsletter here. Click here to visit our landing page.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
UnitedHealth Group's (UNH) Healthcare Dominance: A Key Player in the Dogs of the Dow
UnitedHealth Group Incorporated (NYSE:UNH) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A senior healthcare professional giving advice to a patient in a clinic. The stock has dropped over 44% so far this year after reporting weaker-than-expected earnings in the first quarter. The company first reduced its full-year outlook and later chose to withdraw it entirely. Even with the underwhelming Q1 performance, UnitedHealth Group Incorporated (NYSE:UNH) still posted a 9.8% year-over-year increase in revenue, reaching $109.6 billion. It earned a profit of around $6.3 billion during the quarter and maintained a solid financial position, holding close to $34.3 billion in cash and cash equivalents, along with a debt level that remains manageable. The company has added 780,000 new members so far this year. Meanwhile, Optum Health still expects to provide value-based care to an additional 650,000 patients in 2025. In addition, UnitedHealth Group Incorporated (NYSE:UNH) generated $5.5 billion in operating cash flow during the quarter and returned $5 billion to investors through dividends and share repurchases. The company has been rewarding shareholders with growing dividends since 2011 and currently offers a quarterly dividend of $2.21 per share. The stock supports a dividend yield of 3.15%, as of July 26. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
3 hours ago
- Forbes
Changes In Prior Approval Coming To Traditional Medicare, Medicare Advantage
There were two major announcements recently regarding prior approval of treatments and services for Medicare beneficiaries. In most medical insurance, many treatments won't be covered unless it is approved first by the insurer. It's been a source of controversy for some time. Original Medicare hasn't required prior authorization of treatments and services, with a few exceptions. For most care, providers and the patient agree on a treatment. After the treatment, paperwork for approval and payment is submitted to Medicare. Medicare recently announced a new model program that will test pre-approval. The voluntary model program will test pre-approval for some services and treatments, according to a recent announcement from the Center for Innovation of the Centers for Medicare and Medicaid Services. The model program is seeking medical providers to volunteer for the program from Jan. 1, 2026 through Dec. 31, 2031. The model will be restricted to New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Providers who volunteer and are accepted will agree to seek prior authorization for 17 items and services, including skin substitutes, deep brain stimulation for Parkinson's Disease, impotence treatment, and arthroscopy for knee osteoarthritis. A provider who volunteers for the program can choose not to seek prior approval for a case. There will be a post-treatment review of the case, and the provider will risk not being paid by Medicare for the treatment. CMS initiated the program and selected the services to be covered because of a series of reports showing waste, fraud or abuse in certain areas. For example, Medicare spent up to $5.8 billion in 2022 on unnecessary or inappropriate services that had no clinical benefit, according to the Medicare Payment Advisory Commission. Under the model, providers will submit the same information they currently submit for payment approval after a service is provided to a beneficiary. The difference is that under the model, the information will be submitted earlier and the provider will wait for approval before performing the services. CMS will select companies to receive and review the prior authorizations. It expects that they will use artificial intelligence and other tools in addition to medical professionals to review the submissions. The companies will be paid based on the extent to which they saved the government money by stopping unnecessary services. CMS said it will manage the program to avoid adverse impact on beneficiaries and providers. There was other news about pre-approval, this time involving Medicare Advantage plans. Pre-approval in Medicare Advantage plans has been controversial recently. There have been a number of recent reports and studies that found the authorization process was delaying treatment or causing patients to abandon treatment plans. Other reports indicated that a high percentage of treatments that initially were denied coverage eventually were approved if the patients or their providers appealed the than 50 major insurers who sponsor many types of insurance plans announced that they will voluntarily streamline prior authorization of treatments and services in all insurance markets, including Medicare Advantage plans. The insurers say they plan to have the new process in place by Jan. 1, 2027.
Yahoo
4 hours ago
- Yahoo
Labcorp Holdings Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Labcorp Holdings (NYSE:LH) Second Quarter 2025 Results Key Financial Results Revenue: US$3.53b (up 9.5% from 2Q 2024). Net income: US$237.9m (up 16% from 2Q 2024). Profit margin: 6.7% (up from 6.4% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$2.85 (up from US$2.44 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Labcorp Holdings Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 12%. Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are up 8.7% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Labcorp Holdings. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.